747 related articles for article (PubMed ID: 23401433)
1. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.
Li T; Kung HJ; Mack PC; Gandara DR
J Clin Oncol; 2013 Mar; 31(8):1039-49. PubMed ID: 23401433
[TBL] [Abstract][Full Text] [Related]
2. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
3. Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities.
Gutierrez ME; Choi K; Lanman RB; Licitra EJ; Skrzypczak SM; Pe Benito R; Wu T; Arunajadai S; Kaur S; Harper H; Pecora AL; Schultz EV; Goldberg SL
Clin Lung Cancer; 2017 Nov; 18(6):651-659. PubMed ID: 28479369
[TBL] [Abstract][Full Text] [Related]
4. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
5. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
7. The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.
Fumagalli C; Vacirca D; Rappa A; Passaro A; Guarize J; Rafaniello Raviele P; de Marinis F; Spaggiari L; Casadio C; Viale G; Barberis M; Guerini-Rocco E
J Clin Pathol; 2018 Sep; 71(9):767-773. PubMed ID: 29535211
[TBL] [Abstract][Full Text] [Related]
8. Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy.
Faber E; Grosu H; Sabir S; San Lucas FA; Barkoh BA; Bassett RL; Luthra R; Stewart J; Roy-Chowdhuri S
J Clin Pathol; 2022 Sep; 75(9):612-619. PubMed ID: 33952592
[TBL] [Abstract][Full Text] [Related]
9. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
[TBL] [Abstract][Full Text] [Related]
10. Personalizing therapy in advanced non-small cell lung cancer.
Villaruz LC; Burns TF; Ramfidis VS; Socinski MA
Semin Respir Crit Care Med; 2013 Dec; 34(6):822-36. PubMed ID: 24258572
[TBL] [Abstract][Full Text] [Related]
11. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
12. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
[TBL] [Abstract][Full Text] [Related]
13. Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer.
Gray J; Thompson JC; Carpenter EL; Elkhouly E; Aggarwal C
Oncologist; 2021 Oct; 26(10):e1812-e1821. PubMed ID: 34216176
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing.
Prabhash K; Advani SH; Batra U; Biswas B; Chougule A; Ghosh M; Muddu VK; Sahoo TP; Vaid AK
Adv Ther; 2019 Apr; 36(4):766-785. PubMed ID: 30864106
[TBL] [Abstract][Full Text] [Related]
15. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Remon J; Pignataro D; Novello S; Passiglia F
Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408
[TBL] [Abstract][Full Text] [Related]
16. Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next-generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice.
Moore DA; Balbi K; Ingham A; Arkenau HT; Bennett P
J Clin Pathol; 2018 Nov; 71(11):1001-1006. PubMed ID: 30054375
[TBL] [Abstract][Full Text] [Related]
17. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
18. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting.
Presley CJ; Tang D; Soulos PR; Chiang AC; Longtine JA; Adelson KB; Herbst RS; Zhu W; Nussbaum NC; Sorg RA; Agarwala V; Abernethy AP; Gross CP
JAMA; 2018 Aug; 320(5):469-477. PubMed ID: 30088010
[TBL] [Abstract][Full Text] [Related]
19. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.
Aggarwal C; Thompson JC; Black TA; Katz SI; Fan R; Yee SS; Chien AL; Evans TL; Bauml JM; Alley EW; Ciunci CA; Berman AT; Cohen RB; Lieberman DB; Majmundar KS; Savitch SL; Morrissette JJD; Hwang WT; Elenitoba-Johnson KSJ; Langer CJ; Carpenter EL
JAMA Oncol; 2019 Feb; 5(2):173-180. PubMed ID: 30325992
[TBL] [Abstract][Full Text] [Related]
20. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
